Note: This document contains side effect information about mecasermin. Some of the dosage forms listed on this page may not apply to the brand name Increlex.
Common side effects of Increlex include: tonsil disease. See below for a comprehensive list of adverse effects.
Applies to mecasermin: subcutaneous solution
Along with its needed effects, mecasermin (the active ingredient contained in Increlex) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking mecasermin:
Incidence not known
Get emergency help immediately if any of the following symptoms of overdose occur while taking mecasermin:
Symptoms of overdose
Some side effects of mecasermin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to mecasermin: subcutaneous solution
The most common adverse events were hypoglycemia, injection site hypertrophy, snoring, hypoacusis, headache, and tonsillar hypertrophy.
Very common (10% or more): Hypoglycemia (47%)
Common (1% to 10%): Hypoglycemic seizure, hyperglycemia, hyperlipidemia, obesity, increased weight
Very common (10% or more): Injection site hypertrophy (32%)
Common (1% to 10%): Injection site pain, injection site bruising, injection site fibrosis, injection site reaction, injection site swelling, injection site induration, injection site pigmentation changes
Postmarketing reports: Pruritus, urticaria, injection site reactions (e.g. erythema, pain, hematoma, hemorrhage, induration, rash, swelling)
Very common (10% or more): Hypoacusis (20%), febrile infection, otitis media, serous otitis media, chronic otitis media serous, otitis externa, ear infection
Common (1% to 10%): Fluid in middle ear, ear pain, abnormal tympanometry, ear tube insertion, otorrhea, ear disorder, middle ear disorder, tympanic membrane disorder, ear congestion, Mucosal membrane hyperplasia, hypertrophy, mucosal edema, asthenia, chest discomfort, abnormal tympanometry, adenotonsillectomy, adenoidectomy, ear tube insertion
Frequency not reported: Elevations in cholesterol, elevations in triglycerides
Very common (10% or more): Snoring (22%), tonsillar hypertrophy (16%), upper respiratory tract infection, pharyngitis, tonsillitis
Common (1% to 10%): Tonsillectomy/adenoidectomy, obstructive sleep apnea, adenoidal hypertrophy, nasal turbinate hypertrophy, dyspnea, nasal mucosal disorder, obstructive airway disorder, abnormal respiration, nasal congestion, mouth breathing
Very common (10% or more): Headache (18%)
Common (1% to 10%): Intracranial hypertension, dizziness, convulsions, febrile convulsion, benign intracranial hypertension, loss of consciousness, sleep apnea syndrome, dizziness, tremor, restless leg syndrome, lethargy
Very common (10% or more): Anti-IGF-1 antibodies (up to 61%), thymus hypertrophy
Common (1% to 10%): Cardiac murmur, cardiomegaly, ventricular hypertrophy, atrial hypertrophy, tachycardia, tachycardia paroxysmal, mitral valve incompetence, tricuspid valve incompetence, abnormal echocardiogram
Frequency not reported: Cardiomegaly/valvulopathy
Tonsillar hypertrophy appears to occur more frequently in the first 1 to 2 years of therapy with lesser tonsillar growth in subsequent years.
Very common (10% or more): Oral candidiasis
Common (1% to 10%): Vomiting, retching, abdominal pain, upper abdominal pain, abdominal distension, dysphagia
Common (1% to 10%): Lipohypertrophy, bruising, skin hypertrophy, acrochordons, abnormal hair texture, pigmented nevus
Frequency not reported: Thickening of the soft tissues of the face
Postmarketing reports: Alopecia, hair texture abnormal
Common (1% to 10%): Increased alanine aminotransferase, increased aspartate aminotransferase
Frequency not reported: Elevated AST, elevated LDH, elevated ALT
Common (1% to 10%): Local and/or systemic hypersensitivity
Postmarketing reports: Anaphylaxis, local allergic reactions, generalized urticaria, angioedema, dyspnea
Common (1% to 10%): Lymphadenopathy
Common (1% to 10%): Arthralgia, pain in extremity, myalgia, scoliosis, spinal deformity, soft tissue disorder, muscle cramp, flank pain, musculoskeletal stiffness, congenital jaw malformation
Postmarketing reports: Osteonecrosis/avascular necrosis (occasionally associated with slipped capital femoral epiphysis)
Common (1% to 10%): Nephrolithiasis, hydronephrosis, renal colic
Frequency not reported: Renal and splenic length increased rapidly
Common (1% to 10%): Papilledema, reduced visual acuity, myopia
Common (1% to 10%): Gynecomastia, ovarian cyst
Common (1% to 10%): Depression, sleep terror, nervousness, abnormal behavior, disorientation
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Increlex